Hirotaka Iwaki

Hirotaka Iwaki

Auto-generated profile, based on publicly available information

Hirotaka Iwaki

Center for Alzheimer's and Related Dementias (CARD), National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in The Lancet Neurology
Verified
Journal Article
Closed access
MNMike A Nalls
Mike A Nalls
CBCornelis Blauwendraat
Cornelis Blauwendraat
KHKarl Heilbron
Karl Heilbron
SBSara Bandres-Ciga
Sara Bandres-Ciga
DCDiana Chang
Diana Chang
FZFutao Zhang
Futao Zhang

7 April 2019 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
CBCornelis Blauwendraat
Cornelis Blauwendraat
KHKarl Heilbron
Karl Heilbron
CMCostanza L. Vallerga Msc
Costanza L. Vallerga Msc
SBSara Bandres‐Ciga
Sara Bandres‐Ciga
FCFriedrich Rainer von Coelln
Friedrich Rainer von Coelln
F(for the International Parkinson's Disease Genomics Consortium (IPDGC)
for the International Parkinson's Disease Genomics Consortium (IPDGC)

22 November 2019 in Brain
Verified
Journal Article
Closed access
PDF file
CBCornelis Blauwendraat
Cornelis Blauwendraat
XRXylena Reed
Xylena Reed
LKLynne Krohn
Lynne Krohn
KHKarl Heilbron
Karl Heilbron
SBSara Bandres-Ciga
Sara Bandres-Ciga
ASAndrew B Singleton
Andrew B Singleton
Parkinson’s disease is a genetically complex disorder. Multiple genes have been shown to contribute to the risk of Parkinson’s disease, and currently 90 independent risk variants have been identified by genome-wide association studies. Thus far, a number of genes (including SNCA, LRRK2, and GBA) have been shown to contain variability across a spectrum of frequency and effect, from rare, highly penetrant variants to common risk alleles with small effect sizes. Variants in GBA, encoding the enzyme glucocerebrosidase, are associated with Lewy body diseases such as Parkinson’s disease and Lewy body dementia. These variants, which reduce or abolish enzymatic activity, confer a spectrum of disease risk, from 1.4- to >10-fold. An outstanding question in the field is what other genetic factors that influence GBA-associated risk for disease, and whether these overlap with known Parkinson’s disease risk variants. Using multiple, large case-control datasets, totalling 217 165 individuals (22 757 Parkinson’s disease cases, 13 431 Parkinson’s disease proxy cases, 622 Lewy body dementia cases and 180 355 controls), we identified 1691 Parkinson’s disease cases, 81 Lewy body dementia cases, 711 proxy cases and 7624 controls with a GBA variant (p.E326K, p.T369M or p.N370S). We performed a genome-wide association study and analysed the most recent Parkinson’s disease-associated genetic risk score to detect genetic influences on GBA risk and age at onset. We attempted to replicate our findings in two independent datasets, including the personal genetics company 23andMe, Inc. and whole-genome sequencing data. Our analysis showed that the overall Parkinson’s disease genetic risk score modifies risk for disease and decreases age at onset in carriers of GBA variants. Notably, this effect was consistent across all tested GBA risk variants. Dissecting this signal demonstrated that variants in close proximity to SNCA and CTSB (encoding cathepsin B) are the most significant contributors. Risk variants in the CTSB locus were identified to decrease mRNA expression of CTSB. Additional analyses suggest a possible genetic interaction between GBA and CTSB and GBA p.N370S induced pluripotent cell-derived neurons were shown to have decreased cathepsin B expression compared to controls. These data provide a genetic basis for modification of GBA-associated Parkinson’s disease risk and age at onset, although the total contribution of common genetics variants is not large. We further demonstrate that common variability at genes implicated in lysosomal function exerts the largest effect on GBA associated risk for disease. Further, these results have implications for selection of GBA carriers for therapeutic interventions.

10 September 2019 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
HIHirotaka Iwaki
Hirotaka Iwaki
CBCornelis Blauwendraat
Cornelis Blauwendraat
HLHampton L. Leonard
Hampton L. Leonard
JKJonggeol J. Kim
Jonggeol J. Kim
GLGanqiang Liu
Ganqiang Liu
MNMike A. Nalls
Mike A. Nalls

28 October 2020 in Movement Disorders
Verified
Journal Article
Open access
PDF file
MTManuela M.X. Tan
Manuela M.X. Tan
MLMichael A. Lawton
Michael A. Lawton
EJEdwin Jabbari
Edwin Jabbari
RRRegina H. Reynolds
Regina H. Reynolds
HIHirotaka Iwaki
Hirotaka Iwaki
HMHuw R. Morris
Huw R. Morris
Background: There are currently no treatments that stop or slow the progression of Parkinson's disease (PD). Case–control genome‐wide association studies have identified variants associated with disease risk, but not progression. The objective of the current study was to identify genetic variants associated with PD progression.Methods: We analyzed 3 large longitudinal cohorts: Tracking Parkinson's, Oxford Discovery, and the Parkinson's Progression Markers Initiative. We included clinical data for 3364 patients with 12,144 observations (mean follow‐up 4.2 years). We used a new method in PD, following a similar approach in Huntington's disease, in which we combined multiple assessments using a principal components analysis to derive scores for composite, motor, and cognitive progression. These scores were analyzed in linear regression in genome‐wide association studies. We also performed a targeted analysis of the 90 PD risk loci from the latest case–control meta‐analysis.Results: There was no overlap between variants associated with PD risk, from case–control studies, and PD age at onset versus PD progression. The APOE ε4 tagging variant, rs429358, was significantly associated with composite and cognitive progression in PD. Conditional analysis revealed several independent signals in the APOE locus for cognitive progression. No single variants were associated with motor progression. However, in gene‐based analysis, ATP8B2, a phospholipid transporter related to vesicle formation, was nominally associated with motor progression (P = 5.3 × 10−6).Conclusions: We provide early evidence that this new method in PD improves measurement of symptom progression. We show that the APOE ε4 allele drives progressive cognitive impairment in PD. Replication of this method and results in independent cohorts are needed. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

1 August 2019 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
HIHirotaka Iwaki
Hirotaka Iwaki
CBCornelis Blauwendraat
Cornelis Blauwendraat
HLHampton L. Leonard
Hampton L. Leonard
GLGanqiang Liu
Ganqiang Liu
JMJodi Maple-Grødem
Jodi Maple-Grødem
MNMike A. Nalls
Mike A. Nalls
Objective To determine if any association between previously identified alleles that confer risk for Parkinson disease and variables measuring disease progression. Methods We evaluated the association between 31 risk variants and variables measuring disease progression. A total of 23,423 visits by 4,307 patients of European ancestry from 13 longitudinal cohorts in Europe, North America, and Australia were analyzed. Results We confirmed the importance of GBA on phenotypes. GBA variants were associated with the development of daytime sleepiness (p.N370S: hazard ratio [HR] 3.28 [1.69–6.34]) and possible REM sleep behavior (p.T408M: odds ratio 6.48 [2.04–20.60]). We also replicated previously reported associations of GBA variants with motor/cognitive declines. The other genotype-phenotype associations include an intergenic variant near LRRK2 and the faster development of motor symptom (Hoehn and Yahr scale 3.0 HR 1.33 [1.16–1.52] for the C allele of rs76904798) and an intronic variant in PMVK and the development of wearing-off effects (HR 1.66 [1.19–2.31] for the C allele of rs114138760). Age at onset was associated with TMEM175 variant p.M393T (−0.72 [−1.21 to −0.23] in years), the C allele of rs199347 (intronic region of GPNMB, 0.70 [0.27–1.14]), and G allele of rs1106180 (intronic region of CCDC62, 0.62 [0.21–1.03]). Conclusions This study provides evidence that alleles associated with Parkinson disease risk, in particular GBA variants, also contribute to the heterogeneity of multiple motor and nonmotor aspects. Accounting for genetic variability will be a useful factor in understanding disease course and in minimizing heterogeneity in clinical trials.